Dyadic International vs Marker Therapeutics
Dyadic International and Marker Therapeutics are similar in size: $3.1m and $3.5m of revenue in their latest fiscal years. Dyadic International grew faster (-11.6% against -46.2%). Dyadic International kept more of each dollar of sales as profit: a net margin of -238.3% against -343.0%. Dyadic International carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Dyadic InternationalDYAI, 2025 | Marker TherapeuticsMRKR, 2025 |
|---|---|---|
| Revenue | $3.1m | $3.5m |
| Revenue growth | -11.6% | -46.2% |
| Net income | −$7.4m | −$12.2m |
| Operating margin | -232.8% | -363.5% |
| Net margin | -238.3% | -343.0% |
| Return on equity | — | -68.8% |
| Free cash flow | — | −$12.0m |
| Cash | $4.6m | $16.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 5 | 5 |
| Market value | $13.2m | $16.5m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 3 sales | 0 buys, 0 sales |